Considering Triplet Therapy for Nondriver NSCLC
Videos
Second-Line Therapy in Extranodal Marginal Zone Lymphoma
Perspective on Treating Advanced Marginal Zone Lymphoma
David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Mayer on Giredestrant's Success in Early Breast Cancer
2
PLT012 Receives IND Clearance from FDA for Solid Tumors
3
Sacituzumab Govitecan: Elevating Quality of Life in First-Line TNBC
4
Targeting HER2-Low Breast Cancer: the ARX788 Phase 2 Clinical Trial
5